TransMedics Group, Inc. (BIT:1TMDX)

Market Cap	3.61B +54.7%
Revenue (ttm)	515.70M +37.1%
Net Income	162.07M +436.6%
EPS	4.15 +382.5%
Shares Out	n/a
PE Ratio	22.27
Forward PE	41.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	16
Open	n/a
Previous Close	105.65
Day's Range	n/a
52-Week Range	78.74 - 129.65
Beta	n/a
RSI	39.16
Earnings Date	Feb 24, 2026

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1998
• Employees: 898
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1TMDX

Financial Performance

In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.

Financial numbers in USD